Cadrenal Therapeutics, Inc. (CIK: 0001937993) EDGAR, Information, Filings... CompaniesBIO.Com

Cadrenal Therapeutics, Inc.

Mailing address
822 A1A NORTH, SUITE 300, PONTE VEDRA, Delaware, 32082
Phone
904-300-0701
State location
Florida
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
Filings
N/A

Cadrenal Therapeutics, Inc. (CIK: 0001937993) is an American company incorporated in the state of Florida. Head office is located at 822 A1A NORTH, SUITE 300, PONTE VEDRA, Florida, 32082. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. Cadrenal Therapeutics, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Lisicki Robert	0001779614	Jul-23-2023	director
MURPHY JOHN RAYMOND	0001275195	Jan-19-2023	director
Szot Matthew K	0001401385	Jan-19-2023	officer: Chief Financial Officer
Pham Quang X	0001405290	Jan-19-2023	director, 10 percent owner, officer: CEO and Chairman
WILSON GLYNN	0001405625	Jan-19-2023	director
Zelenkofske Steven	0001578333	Jan-19-2023	director
LOSORDO DOUGLAS W	0001583810	Jan-19-2023	officer: Chief Medical Officer

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Cadrenal Therapeutics, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
SCHEDULE 13G	Document	Acc-no: 0001193125-26-339234 (34 Act) Size: KB	Aug-07-2026	005-94027 261251486
DEFA14A	Document	Additional definitive proxy solicitation materials Acc-no: 0001213900-26-084716 (34 Act) Size: KB	Aug-03-2026	001-41596 261234378
ARS	Document	Annual report to security holders Acc-no: 0001213900-26-084713 (34 Act) Size: KB	Aug-03-2026	001-41596 261234355
DEF 14A	Document	Definitive proxy statements Acc-no: 0001213900-26-084710 (34 Act) Size: KB	Aug-03-2026	001-41596 261234337
PRE 14A	Document	Preliminary proxy statement not related to a contested matter or merger/acquisition Acc-no: 0001213900-26-081012 (34 Act) Size: KB	Jul-23-2026	001-41596 261197928
8-K	Document	Current report filing Acc-no: 0001213900-26-079824 (34 Act) Size: KB	Jul-21-2026	001-41596 261188210
EFFECT	Document	Acc-no: 9999999995-26-002367 (33 Act) Size: KB	Jul-20-2026	333-297432 261188072
424B3	Document	Prospectus filed pursuant to Rule 424(b)(3) Acc-no: 0001213900-26-079648 (33 Act) Size: KB	Jul-20-2026	333-297432 261187208
8-K	Document	Current report filing Acc-no: 0001213900-26-079176 (34 Act) Size: KB	Jul-17-2026	001-41596 261183895
D	Document	Acc-no: 0001213900-26-078373 (33 Act) Size: KB	Jul-15-2026	021-590962 261177948
S-3	Document	Registration statement for specified transactions by certain issuers Acc-no: 0001213900-26-077647 (33 Act) Size: KB	Jul-13-2026	333-297432 261171980
8-K	Document	Current report filing Acc-no: 0001213900-26-077134 (34 Act) Size: KB	Jul-10-2026	001-41596 261168774
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001213900-26-074557 ( Act) Size: 0 KB	Jul-01-2026
8-K	Document	Current report filing Acc-no: 0001213900-26-074421 (34 Act) Size: KB	Jul-01-2026	001-41596 261146605
8-K	Document	Current report filing Acc-no: 0001213900-26-073213 (34 Act) Size: KB	Jun-29-2026	001-41596 261136947
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001213900-26-072789 ( Act) Size: 0 KB	Jun-26-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001213900-26-071578 ( Act) Size: 0 KB	Jun-24-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001213900-26-070248 ( Act) Size: 0 KB	Jun-18-2026
8-K	Document	Current report filing Acc-no: 0001213900-26-069902 (34 Act) Size: KB	Jun-18-2026	001-41596 261100574
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001213900-26-068981 ( Act) Size: 0 KB	Jun-15-2026

Recent 20 filings. View all Cadrenal Therapeutics, Inc. filings

Overall rating 5.0

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Cadrenal Therapeutics, Inc. overview
Cadrenal Therapeutics, Inc. job
Cadrenal Therapeutics, Inc. stock
Cadrenal Therapeutics, Inc. ownership
Cadrenal Therapeutics, Inc. CEO
Cadrenal Therapeutics, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.